DE69123361D1 - Verwendung von interleukin-4 zur behandlung der festen tumoren - Google Patents

Verwendung von interleukin-4 zur behandlung der festen tumoren

Info

Publication number
DE69123361D1
DE69123361D1 DE69123361T DE69123361T DE69123361D1 DE 69123361 D1 DE69123361 D1 DE 69123361D1 DE 69123361 T DE69123361 T DE 69123361T DE 69123361 T DE69123361 T DE 69123361T DE 69123361 D1 DE69123361 D1 DE 69123361D1
Authority
DE
Germany
Prior art keywords
pct
solid tumors
interleukin
treating solid
date mar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69123361T
Other languages
English (en)
Other versions
DE69123361T2 (de
Inventor
Marian Plunkett
Joseph Catino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE69123361D1 publication Critical patent/DE69123361D1/de
Application granted granted Critical
Publication of DE69123361T2 publication Critical patent/DE69123361T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DE69123361T 1990-09-06 1991-09-03 Verwendung von interleukin-4 zur behandlung der festen tumoren Expired - Fee Related DE69123361T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57896890A 1990-09-06 1990-09-06
PCT/US1991/006126 WO1992004044A1 (en) 1990-09-06 1991-09-03 Use of il-4 to treat solid tumors

Publications (2)

Publication Number Publication Date
DE69123361D1 true DE69123361D1 (de) 1997-01-09
DE69123361T2 DE69123361T2 (de) 1997-04-30

Family

ID=24315064

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69123361T Expired - Fee Related DE69123361T2 (de) 1990-09-06 1991-09-03 Verwendung von interleukin-4 zur behandlung der festen tumoren

Country Status (12)

Country Link
US (1) US5382427A (de)
EP (1) EP0552243B1 (de)
JP (1) JPH06501017A (de)
KR (1) KR100229974B1 (de)
AT (1) ATE145556T1 (de)
AU (1) AU661979B2 (de)
CA (1) CA2091170A1 (de)
DE (1) DE69123361T2 (de)
DK (1) DK0552243T3 (de)
GR (1) GR3022321T3 (de)
HU (1) HU215389B (de)
WO (1) WO1992004044A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0490006B1 (de) * 1990-12-13 1994-06-22 Schering-Plough Pharmazeutische Zusammensetzungen zur Behandlung von bösartigen B-Zellenkrankheiten
US5679338A (en) * 1994-05-12 1997-10-21 Osteoarthritis Science, Inc. Use of IL-4 for inhibition of the breakdown of articular cartilage and other tissues
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5716612A (en) * 1994-09-07 1998-02-10 Schering Corporation Use of IL-4 for potentiation of chemotherapeutic agents
EP0815204B1 (de) * 1995-03-17 2006-09-06 The Regents Of The University Of California Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen
US20080220025A1 (en) * 1995-03-17 2008-09-11 James Thompson Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells
US7361332B2 (en) * 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
RU2115429C1 (ru) * 1997-07-22 1998-07-20 Закрытое акционерное общество "Фосфосорб" Рекомбинантный иммунотоксин на основе дифтерийного токсина и интерлейкина-2 (дт 482-il2) и способ его получения
PT1520588E (pt) * 1998-07-13 2015-03-31 Univ Texas Usos de anticorpos para amino fosfolípidos para o tratamento do cancro
AU750414B2 (en) * 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6406693B1 (en) * 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
CA2447360A1 (en) * 2001-05-09 2002-11-14 Alk-Abello A/S Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
EP4285913A1 (de) * 2022-05-30 2023-12-06 Ecole Polytechnique Fédérale de Lausanne (EPFL) Hochwirksame adoptive t-zelltherapie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3882611T2 (de) * 1987-08-03 1993-12-23 Tasuku Honjo Menschliches Interleukin-4, Expressionsvektoren dafür und diese enthaltende Transformanten.
US4958007A (en) * 1988-05-17 1990-09-18 Schering-Plough Corp. Extraction of human interleukin-4- from bacteria

Also Published As

Publication number Publication date
HU215389B (hu) 1998-12-28
KR100229974B1 (ko) 1999-11-15
EP0552243A1 (de) 1993-07-28
JPH06501017A (ja) 1994-01-27
WO1992004044A1 (en) 1992-03-19
AU661979B2 (en) 1995-08-17
AU8850591A (en) 1992-03-30
DK0552243T3 (da) 1997-03-10
US5382427A (en) 1995-01-17
GR3022321T3 (en) 1997-04-30
DE69123361T2 (de) 1997-04-30
CA2091170A1 (en) 1992-03-07
HUT63769A (en) 1993-10-28
EP0552243B1 (de) 1996-11-27
HU9300624D0 (en) 1993-05-28
ATE145556T1 (de) 1996-12-15

Similar Documents

Publication Publication Date Title
DE69123361D1 (de) Verwendung von interleukin-4 zur behandlung der festen tumoren
DE69424915D1 (de) Verwendung von 1-2-4-Benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
ATE203421T1 (de) Keime von kobalt-palladium zur thermischen behandlung von tumoren
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
DE69331045D1 (de) Verwendung von igf-1
DE69228749D1 (de) Neuartige polypeptide und ihre verwendung
ATE143260T1 (de) Verwendung von (s)-isofluran und (s)-desfluran zur anästhesie sowie entsprechende arzneimittelzubereitungen
DK471386D0 (da) Farmaceutisk komposition til behandling af leukopeni
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
ATE220923T1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
ATE174629T1 (de) Herstellung von proteinen mittels protein 7b2
ATE125709T1 (de) Verwendung von ifn-gamma zur herstellung einer pharmazeutischen zusammensetzung für die behandlung von atl.
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
ATE97575T1 (de) Verwendung eines polypeptids mit interleukin 2aktivit|t zur herstellung einer zur behandlung von einfachen pleurageschwueren bestimmten pharmazeutischen zusammensetzung.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
ATE59780T1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
ATE225183T1 (de) Verwendung von hepatozyten-wachstumsfaktor zur induzierung der proliferation und differenzierung von hämatopoietischen zellen
DE3881703D1 (de) Behandlung zur verbesserung der eigenschaften von keratintextilmaterialien.
DE69131058D1 (de) Verwendung einer therapeutischen Zusammensetzung zur Behandlung von Bronchitis
ATE135232T1 (de) Pharmazeutische zusammensetzungen zur behandlung von b-zell-entartungen
ATE68474T1 (de) Aktive substanz in der kardiovaskulaeren therapie.
FI952855A (fi) Uudet triatsolokinatsoliinit, niiden valmistus ja käyttö

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee